Murray Epstein
#107,910
Most Influential Person Now
Murray Epstein's AcademicInfluence.com Rankings
Murray Epsteinphilosophy Degrees
Philosophy
#4438
World Rank
#6949
Historical Rank
Logic
#1887
World Rank
#2752
Historical Rank
Murray Epsteinbiology Degrees
Biology
#5784
World Rank
#8350
Historical Rank
Physiology
#138
World Rank
#298
Historical Rank
Download Badge
Philosophy Biology
Murray Epstein's Degrees
- PhD Physiology University of Miami
- Doctorate Medicine University of Miami
Why Is Murray Epstein Influential?
(Suggest an Edit or Addition)Murray Epstein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis (1988) (1523)
- Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. (2000) (1253)
- Diabetes, Hypertension, and Cardiovascular Disease: An Update (2001) (1077)
- Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. (2003) (461)
- Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. (1995) (460)
- Diabetes mellitus and hypertension. (1992) (435)
- Renal failure in the patient with cirrhosis. The role of active vasoconstriction. (1970) (413)
- Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. (2006) (400)
- Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension (2009) (358)
- ACUTE OLIGURIC RENAL FAILURE IN MAN: EVIDENCE FOR PREFERENTIAL RENAL CORTICAL ISCHEMIA (1968) (305)
- SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach (2000) (292)
- Renin-Angiotensin System Blockers and the COVID-19 Pandemic (2020) (288)
- Aging and the kidney. (1996) (261)
- Effects of calcium antagonists on renal hemodynamics. (1985) (247)
- Renal effects of head-out water immersion in man: implications for an understanding of volume homeostasis. (1978) (237)
- Renal effects of head-out water immersion in humans: a 15-year update. (1992) (192)
- Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. (2015) (186)
- The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. (1999) (170)
- Characterization of the renin-aldosterone system in decompensated cirrhosis. (1977) (152)
- The Kidney in liver disease (1996) (150)
- Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. (2001) (145)
- Renal hemodynamic effects of calcium antagonists. (1987) (143)
- Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. (1996) (143)
- Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. (1992) (138)
- Age as a determinant of renal sodium conservation in normal man. (1976) (133)
- Pressure-Induced Vasoconstriction of Renal Microvessels in Normotensive and Hypertensive Rats: Studies in the Isolated Perfused Hydronephrotic Kidney (1989) (133)
- Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans. (1987) (132)
- Direct visualization of effects of endothelin on the renal microvasculature. (1990) (125)
- Effects of water immersion to the neck on pulmonary circulation and tissue volume in man. (1976) (125)
- Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. (2005) (124)
- OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria (2002) (118)
- Disparate effects of calcium antagonists on renal microcirculation. (1996) (116)
- Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. (2006) (111)
- Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. (1992) (109)
- Potential of dopamine A-1 agonists in the management of acute renal failure. (1998) (109)
- Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. (1983) (108)
- Calcium Antagonists in Clinical Medicine (1992) (106)
- Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. (1989) (102)
- Deranged sodium homeostasis in cirrhosis. (1979) (100)
- Effects of aging on the kidney. (1979) (95)
- Cardiovascular and renal effects of head-out water immersion in man: application of the model in the assessment of volume homeostasis. (1976) (93)
- Determinants of deranged sodium and water homeostasis in decompensated cirrhosis. (1976) (91)
- Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. (2012) (89)
- Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. (2016) (89)
- "No man's land" of the renal vasculature. An arteriographic and hemodynamic assessment of the interlobar and arcuate arteries in essential and accelerated hypertension. (1969) (89)
- Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. (1988) (87)
- Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. (2003) (77)
- Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. (1994) (76)
- Effect of sodium balance on intrarenal distribution of blood flow in normal man. (1970) (74)
- Renal hemodynamic effects of calcium antagonists. (1987) (74)
- Characterization of the natriuresis caused in normal man by immersion in water. (1972) (74)
- Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. (2001) (72)
- Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics (2011) (70)
- Derangements of renal water handling in liver disease. (1985) (68)
- Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. (1994) (68)
- Importance of Potassium in Cardiovascular Disease (2002) (68)
- Relationship between Renal Prostaglandin E and Renal Sodium Handling during Water Immersion in Normal Man (1979) (67)
- Cytoplasmic granularity of the renal medullary interstitial cells in experimental hypertension. (1969) (67)
- Effect of water immersion on renin-aldosterone and renal sodium handling in normal man. (1971) (66)
- Suppression of plasma renin and plasma aldosterone during water immersion in normal man. (1975) (66)
- Effect of intrarenal furosemide on renal function and intratenal hemodynamics in acute renal failure. (1975) (64)
- Pathophysiology of ascites and functional renal failure in cirrhosis. (1988) (64)
- Diabetes, Hypertension, and Cardiovascular Disease (2001) (62)
- Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys. (1991) (62)
- Prevention of radiocontrast-induced nephropathy. (2004) (62)
- H(+)-induced vasodilation of rat aorta is mediated by alterations in intracellular calcium sequestration. (1990) (61)
- Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. (1996) (61)
- Calcium Antagonists and Renal Protection: Current Status and Future Perspectives (1992) (60)
- Familial hyperkalemia, hypertension, and hyporeninemia with normal aldosterone levels. A tubular defect in potassium handling. (1978) (60)
- Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. (2002) (58)
- Presence of a natriuretic factor in urine of normal men undergoing water immersion. (1978) (58)
- "Magnification phenomenon" in chronic renal disease. (1978) (57)
- Isoosmotic central blood volume expansion suppresses plasma arginine vasopressin in normal man. (1981) (57)
- Renal Parenchymal Hypertension: current concepts of pathogenesis and management. (1996) (57)
- Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? (2005) (57)
- Pathophysiology of diabetic nephropathy. (1998) (56)
- Attenuation of endothelin effects by a chloride channel inhibitor, indanyloxyacetic acid. (1992) (56)
- Suppression of ADH during water immersion in normal man. (1975) (56)
- Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition. (1997) (55)
- Atrial Natriuretic Factor and Liver Disease (1993) (55)
- Renin secretion in essential and accelerated hypertension. (1969) (55)
- Calcium antagonists and the kidney. (1987) (54)
- Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome (1982) (54)
- Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. (1999) (54)
- Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. (1992) (54)
- Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused rat kidney. (1987) (53)
- Calcium antagonists should continue to be used for first-line treatment of hypertension. (1995) (52)
- Renin secretion in the patient with hypertension. Relationship to intrarenal blood flow distribution. (1969) (52)
- Reversal by the calcium antagonist nisoldipine of norepinephrine-induced reduction of GFR: evidence for preferential antagonism of preglomerular vasoconstriction. (1985) (51)
- Renal prostaglandins and the control of renal function in liver disease. (1986) (51)
- Effects of water immersion on renal hemodynamics in normal man. (1976) (51)
- Resistant Hypertension: Prevalence and Evolving Concepts (2007) (50)
- Enhanced myogenic responsiveness of renal interlobular arteries in spontaneously hypertensive rats. (1992) (50)
- Relationship of systemic and intrarenal hemodynamics in cirrhosis. (1977) (50)
- Augmentation of prostaglandin production by linoleic acid in man. (1982) (49)
- Effects of water immersion on atrial natriuretic peptide release in humans. (1989) (48)
- Calcium Antagonists and the Kidney: Implications for Renal Protection (1992) (48)
- Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. (2016) (48)
- Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists. (1987) (48)
- Calcium antagonists: still appropriate as first line antihypertensive agents. (1996) (48)
- Statins in the management of dyslipidemia associated with chronic kidney disease (2012) (47)
- Characterization of renal prostaglandin E responsiveness in decompensated cirrhosis: implications for renal sodium handling. (1982) (47)
- Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin. (1993) (46)
- Reversal of renal and smooth muscle actions of the thromboxane mimetic U-44069 by diltiazem. (1986) (46)
- Manned space flight and the kidney. (1991) (45)
- Beta-blockers and the kidney. (1982) (45)
- Volume status as a determinant of the influence of renal PGE on renal function. (1980) (43)
- Renal microvascular actions of calcium antagonists. (1990) (42)
- Determinants of renal actions of atrial natriuretic peptide. Lack of effect of atrial natriuretic peptide on pressure-induced vasoconstriction. (1990) (41)
- Effects of diltiazem and manganese renal hemodynamics: studies in the isolated perfused rat kidney. (1985) (41)
- Management of magnesium depletion. (1988) (40)
- Multiple factors contribute to acetylcholine-induced renal afferent arteriolar vasodilation during myogenic and norepinephrine- and KCl-induced vasoconstriction. Studies in the isolated perfused hydronephrotic kidney. (1994) (40)
- Renal Sodium Handling in Cirrhosis (1982) (39)
- Lercanidipine: a novel dihydropyridine calcium-channel blocker. (2001) (39)
- Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study (2002) (39)
- Increases in circulating atrial natriuretic factor during immersion-induced central hypervolaemia in normal humans. (1986) (39)
- Comparison of water immersion and saline infusion as a means of inducing volume expansion in man. (1975) (39)
- Fixed-dose combination medications for the treatment of hypertension: a critical review. (1987) (38)
- Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. (1984) (38)
- Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation? (2015) (38)
- Effects of water immersion on plasma catecholamines in decompensated cirrhosis. Implications for deranged sodium and water homeostasis. (1985) (37)
- Acid-base aspects of ketoacidosis. (1984) (36)
- Effects of amlodipine on renal hemodynamics. (1989) (35)
- Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction (2002) (35)
- Extracorporeal blood purification in the management of patients with hepatic failure. (1997) (34)
- Atrial natriuretic factor in patients with liver disease. (1989) (33)
- Relationship between plasma ANF responsiveness and renal sodium handling in cirrhotic humans. (1989) (32)
- Effects of water immersion on arginine vasopressin release in humans. (1988) (32)
- Direct evidence that thromboxane mimetic U44069 preferentially constricts the afferent arteriole. (1997) (32)
- Effects of water immersion on sympathoadrenal and dopa-dopamine systems in humans. (1992) (31)
- Beta blockers and renal function: a reappraisal. (1985) (30)
- Use of centrally acting sympatholytic agents in the management of hypertension. (1991) (29)
- Hypertension and chronic kidney disease progression: why the suboptimal outcomes? (2012) (29)
- Renal Vascular Response to Salt Restriction in Normal Man: Evidence Against Adrenergic Mediation (1971) (29)
- Hepatorenal syndrome: emerging perspectives. (1997) (28)
- Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435. (1993) (28)
- Effects of water immersion on plasma catecholamines in normal humans. (1983) (28)
- Calcium antagonists and the kidney: implications for renal protection. (1992) (27)
- Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. (2016) (27)
- Matrix Gla-Protein (MGP) Not Only Inhibits Calcification in Large Arteries But Also May Be Renoprotective: Connecting the Dots (2016) (27)
- Deterioration of renal function with demeclocycline administration. (1976) (27)
- Calcium antagonists and the kidney: future therapeutic perspectives. (1993) (27)
- Renal, endocrine and hemodynamic effects of water immersion in man. (1984) (26)
- Increased sympathetic activity in cirrhosis. (1983) (26)
- Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. (2016) (25)
- Diabetes and hypertension: the bad companions. (1997) (25)
- Calcium antagonists and the kidney. (1991) (25)
- Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer (2016) (25)
- The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. (1996) (24)
- Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics (2017) (24)
- Comparative Effects on Dynamic Renal Potassium Excretion of ACE Inhibition versus Angiotensin Receptor Blockade in Hypertensive Patients with Type II Diabetes Mellitus (2002) (24)
- Natriuretic hormone and the sodium retention of cirrhosis. (1981) (24)
- Comparison of the effects of water immersion and saline infusion on central haemodynamics in man. (1977) (24)
- The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk. (1997) (24)
- RELATIONSHIPS BETWEEN INTRARENAL PERFUSION AND FUNCTION: SERIAL HEMODYNAMIC STUDIES IN THE TRANSPLANTED HUMAN KIDNEY (1972) (23)
- Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. (2001) (23)
- Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. (1997) (23)
- Renal sodium handling in cirrhosis: a reappraisal. (1979) (23)
- Metabolism of arginine by the isolated perfused rat kidney. (1978) (23)
- Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. (2015) (22)
- Are calcium antagonists proarrhythmic? (1997) (22)
- The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy (2007) (22)
- Current strategies for management of hypertensive renal disease. (1999) (22)
- Comparison of the suppressive effects of water immersion and saline administration on renin-aldosterone in normal man. (1979) (21)
- New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. (2016) (21)
- Calcium antagonists and the kidney. Implications for renal protection. (1993) (20)
- Calcium antagonists and renal protection: emerging perspectives. (1998) (20)
- Pathogenesis of Renal Sodium Handling in Cirrhosis (1983) (20)
- Water immersion and the kidney: implications for volume regulation. (1984) (20)
- Flow-induced errors in estimating perfusion pressure of the isolated rat kidney. (1982) (20)
- Depth of Immersion as a Determinant of the Natriuresis of Water Immersion (1974) (19)
- Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. (1982) (19)
- Effects of simulated high altitude on renin-aldosterone and Na homeostasis in normal man. (1972) (19)
- Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present (2021) (18)
- Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy (2006) (18)
- Activation mechanisms of human renal artery: effects of KCl, norepinephrine and nitrendipine upon tension development and 45Ca influx. (1984) (18)
- Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Chronic Renal Disease (1993) (18)
- Interrelationship of renal sodium and phosphate handling in cirrhosis. (1982) (17)
- Release of Kaliuretic Peptide During Immersion-Induced Central Hypervolemia in Healthy Humans (1995) (17)
- Slowly acting calcium antagonists and their merits. (1997) (17)
- Relationship between urine flow rate and prostaglandin E excretion in human beings. (1985) (17)
- Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease (2009) (17)
- Effect of ethacrynic acid and chlorothiazide on intrarenal hemodynamics in normal man. (1971) (16)
- Beta-blockers and the kidney: implications for renal function and renin release. (1985) (16)
- Calcium antagonists and renal protection. Current status and future perspectives. (1992) (16)
- Calcium antagonists and renal disease. (1998) (16)
- The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials (2016) (16)
- Calcium antagonists and diabetic nephropathy. (1991) (16)
- Effects of vasopressin administration on diuresis of water immersion in normal humans. (1981) (16)
- Aging and the kidney: clinical implications. (1985) (15)
- Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. (1993) (15)
- Increased release of the N-terminal and C-terminal portions of the atrial natriuretic factor prohormone during immersion-induced central hypervolemia in cirrhotic humans. (1991) (15)
- Renal hemodynamic effects of calcium antagonists. (1987) (14)
- Spectrum of deranged sodium homeostasis in essential hypertension. (1986) (14)
- Hyperkalemia as a Constraint to Therapy With Combination Renin‐Angiotensin System Blockade: The Elephant in the Room (2009) (14)
- Potassium homeostasis and dyskalemias: the respective roles of renal, extrarenal, and gut sensors in potassium handling. (2016) (14)
- Comparative Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Patients with and without Type II Diabetes Mellitus (2001) (13)
- Diabetes Mellitus and Hypertension, Emerging Therapeutic Perspectives (1995) (13)
- Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) Era. (2016) (13)
- Dopamine‐1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast‐Induced Nephropathy (2004) (12)
- Characterization of renal response to prolonged immersion in normal man. (1980) (12)
- Hepatorenal syndrome following hemihepatectomy. (1976) (12)
- Continuous Arterio-Venous Ultrafiltration in Cirrhotic Patients with Ascites or Renal Failure (1986) (12)
- Cyclooxygenase-2 expression and function in renal pathophysiology. (2002) (12)
- Hypertension as a risk factor for progression of chronic renal disease. (1994) (12)
- Survival in patients treated with continuous arteriovenous hemodialysis for acute renal failure and chronic renal failure. Preliminary observations. (1991) (12)
- Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat (1996) (11)
- Recent landmark clinical trials: how do they modify the therapeutic paradigm? (2002) (11)
- Impairment of Afferent Arteriolar Myogenic Responsiveness in the Galactose-Fed Rat (1994) (11)
- Natriuretic Effects of Calcium Antagonists in Humans: A Review of Experimental Evidence and Clinical Data (1991) (11)
- Relationship between urinary kallikrein and renal sodium handling during water immersion in normal man. (1980) (11)
- Increased release of kaliuretic peptide during immersion-induced central hypervolemia in cirrhotic humans. (1996) (11)
- Modification by Dihydropyridine‐Type Calcium Antagonists of the Renal Hemodynamic Response to Vasoconstrictors (1987) (11)
- ACUTE RENAL FAILURE FOLLOWING RETROGRADE PYELOGRAPHY. (1965) (10)
- The Pattern of the Renal Vascular Response to Epinephrine in Man 1 (1970) (10)
- Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease. (2014) (10)
- Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be? (2006) (10)
- Volume as a determinant of plasma aldosterone in anephric man. (1978) (10)
- Nitrendipine-Induced Stimulation of Renin Release by the Isolated Perfused Rat Kidney (1985) (10)
- Surrogate endpoints and renal protection: focus on microalbuminuria. (1997) (10)
- Diagnosis and management of hypertensive emergencies. (1999) (10)
- Effects of an anti-G suit on the hemodynamic and renal responses to positive (+Gz) acceleration. (1974) (9)
- Renal complications of liver disease. (1985) (9)
- Renal 'salt wasting' despite apparently normal renal, adrenal and central nervous system function. (1979) (9)
- Calcium antagonists and the kidney: implications for renal protection. (1993) (8)
- Review: Relationship between Erythropoietin Administration and Alterations of Renin-Angiotensin-Aldosterone (2006) (8)
- The intersection of Mineralocorticoid Receptor (MR) activation and the FGF23 - Klotho cascade. A Duopoly that promotes renal and cardiovascular injury. (2021) (8)
- [Hepatorenal syndrome]. (1989) (8)
- A forgotten chapter in the history of the renal circulation: the Josep Trueta and Homer Smith intellectual conflict. (2015) (8)
- Calcium antagonists and the progression of chronic renal failure. (1998) (8)
- Lidocaine pharmacokinetics during water immersion in normal humans. (1989) (8)
- Uptake and release of amino acids by normal and remnant kidneys: studies in the isolated perfused rat kidney. (1980) (8)
- Calcium antagonists and renal hemodynamics: implications for renal protection. (1991) (8)
- Calcium antagonists and the kidney. (1988) (8)
- The use of calcium antagonists in the treatment of hypertensive persons with kidney disease (2002) (8)
- Failure of water immersion to influence parathyroid hormone secretion and renal phosphate handling in normal man. (1976) (8)
- Dissociation of Aldosterone and 17-Hydroxycorticosteroid (17-OHCS) Release During Water Immersion in Normal Man 1 , 2 (1971) (7)
- Management of Renal Complications of Liver Disease (1988) (7)
- Hypertension, a Practical Approach (1984) (7)
- Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications. (2001) (7)
- Safety of calcium antagonists (1995) (7)
- Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics. (2004) (7)
- Deranged Renal Function in Liver Disease1 (1977) (6)
- Vascular lesions of the transplanted human kidney--morphologic and hemodynamic studies in chronic rejection. (1968) (6)
- Role of a Third Generation Calcium Antagonist in the Management of Hypertension (2012) (6)
- Video-microscopic assessment of the role of tissue angiotensin-converting enzyme in the control of the renal microcirculation. (1997) (6)
- Functional adaptation to reduction in renal mass: renal handling of amino acids by isolated perfused remnant rat kidneys. (1981) (6)
- Abstract 14271: Patiromer Controls Hyperkalemia in Resistant Hypertensive Patients on RAASi, With Diabetic Kidney Disease (2015) (6)
- Detailed characterization of a tank used for head-out water immersion in humans. (1987) (6)
- Stimulation of Plasma ANF in Cirrhotic Humans by Immersion-Induced Central Hypervolemia (1986) (5)
- Studies of volume homeostasis in man utilizing the model of head-out water immersion. (1978) (5)
- Evolving therapeutic strategies for retarding progression of diabetic nephropathy – an update for 2002 (2002) (5)
- Alcohol and the Kidney (1992) (5)
- Determinants of abnormal renal sodium handling in cirrhosis: a reappraisal. (1980) (5)
- A quantitative assessment of renal blood flow autoregulation in experimental diabetes. (1994) (5)
- Renal hemodynamic effects of calcium antagonists: implications for renal transplantation. (1991) (5)
- Effects of an hyperoxic hypobaric environment on renin-aldosterone in normal man. (1973) (5)
- Calcium Antagonists and the Renal Hemodynamic Response to Vasoconstrictors a (1988) (5)
- Continuous Arterio-Venous Ultrafiltration in the Management of the Renal Complications of Liver Disease (1986) (5)
- P-203: Comparative effects on renal potassium excretion of candesartan versus lisinopril in hypertensive patients with type II diabetes mellitus and preserved renal function* (2001) (4)
- Aldosterone and large artery vessels. (2006) (4)
- Evidence for operation of the magnification phenomenon in patients with chronic renal insufficiency. (1983) (4)
- Unilateral pulmonary changes in acute respiratory distress syndrome of the adult. (1977) (4)
- Aluminum toxicity in chronic renal failure. (1990) (4)
- Arterial calcification and calcium antagonists: what does it mean? (2001) (4)
- Dissociation of renin--aldosterone and renal prostaglandin E during volume expansion induced by immersion in normal man. (1980) (4)
- Role of aldosterone blockade in the management of hypertension and cardiovascular disease. (2004) (4)
- Fixed-dose combination therapy with calcium antagonists. (2002) (3)
- A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden fruit'. (2016) (3)
- Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers (2021) (3)
- Natriuretic Peptides and the Kidney (1994) (3)
- Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease. (1995) (3)
- John P. Merrill: the father of nephrology as a specialty. (2009) (3)
- The hepatorenal syndrome. (1989) (3)
- Avoiding the termination of ACTT. (2020) (3)
- Calcium channel blockers and hypertension: Evolving perspectives—1996 (2004) (3)
- The Growing Role of Calcium Antagonists in Treating Hypertension in the Elderly. (2000) (3)
- Alterations in acid-base homeostasis during water immersion in normal man (1974) (3)
- Hypertension in the elderly (1991) (3)
- Renal sodium retention in liver disease. (1995) (3)
- Hepatorenal Syndrome: A historical appraisal of its origins and conceptual evolution. (2021) (3)
- Effect of prolonged bed rest on renal diluting capacity in normal man. (1971) (3)
- Effects of positive acceleration (+Gz) on renal function and plasma renin in normal man. (1974) (2)
- DEMECLOCYCLINE-INDUCED RENAL FAILURE (1977) (2)
- Evolving role of calcium antagonists in the management of hypertension. (2004) (2)
- OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD (2016) (2)
- The choice of an initial antihypertensive agent. (1986) (2)
- Antihypertensive strategies for preservation of renal function. (1996) (2)
- Renal Disorders in Liver Disease (1991) (2)
- Calcium channel blockers and hypertension: evolving perspective--1996. (1997) (2)
- Hyperkalemia: current concepts and emerging therapeutic options. (2016) (2)
- The hepatorenal syndrome (HRS). (1987) (2)
- Renal dysfunction in a 38-year-old man with hepatic failure. (1983) (2)
- The use of drugs in the patient with uremia. (1969) (2)
- Renal Function in the Choline Deficient Rat' (39103) (1976) (2)
- Addendum Regarding “The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials” (Kidney Int Rep. 2016;1:43–56) (2016) (2)
- Pathogenesis of renal sodium handling in cirrhosis. A reappraisal. (1983) (2)
- Renal Effects of Calcium Antagonists with a Focus on Felodipine (1994) (1)
- A symposium : calcium antagonists and the diabetic patient : recent controversies and future perspectives (1998) (1)
- Pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with type ii diabetes mellitus (2001) (1)
- [Effect of octopamine on arterial pressure and renal function in the normal rat]. (1992) (1)
- H6EFFECTS OF AMLODIPINE AND FOSINOPRIL ALONE AND IN COMBINATION ON RENAL FUNCTION IN HYPERTENSIVE NIDDM PATIENTS WITHOUT CLINICAL NEPHROPATHY (1995) (1)
- Combination drug therapy for high-risk hypertensive patients∗ (2002) (1)
- Hepatorenal Syndrome — Current Concepts of Pathophysiology and Therapy (1995) (1)
- The hepatorenal syndrome pathogenesis and prevention. (1981) (1)
- Atorvastatin does not induce glomerular or tubular dysfunction even at high doses. (2007) (1)
- Calcium channel blockers and hypertension: 2. Safety issues. (1996) (1)
- Patiromer treatment of hyperkalemic resistant hypertension patients with diabetic kidney disease on RAASi normalizes serum potassium and reducing discontinuations secondary to hyperkalemia over 1 year (AMETHYST - DN) (2016) (1)
- C19 - Videomic-roscopic characterization of tissue ACE in the local control of renal hemodynamics (1995) (1)
- Targeting antihypertensive therapy to the individual patient. (1986) (1)
- Newer pharmacologic strategies for retarding progression of renal disease (1997) (0)
- P-245: Differential effects of COX-2 inhibitors on systolic blood pressure in hypertensive patients treated with ACE inhibitors and beta-blockers versus calcium antagonists (2002) (0)
- The future for renal denervation depends on embracing the lessons learned from our previous studies. (2016) (0)
- SO010PATIROMER PROTECTED AGAINST RECURRENT HYPERKALEMIA FOR UP TO 52 WEEKS IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) RECEIVING COMBINED RAAS INHIBITOR THERAPY (2016) (0)
- Calcium antagonists and the kidney. (1989) (0)
- Effects of calcium antagonists on renal hemodynamics. (1990) (0)
- Renal Microcirculation in Essential Hypertension (1991) (0)
- Saturday, May 18, 1:30 AM – 3.30 AM: Combination drug therapy for high-risk hypertensive patients*: Diabetes mellitus: evidence–based rationale for combination therapy (2002) (0)
- The selective DA1 agonist corlopam® for the treatment of acute renal failure: Evidence for augmentation of renal blood flow and natriuresis (1997) (0)
- Norman K. Hollenberg, MD PhD (1936-2020). (2020) (0)
- 16 Alcohol and the Kidney Murray Epstein (0)
- Calcium Antagonists and Glomerular Filtration Rate (1988) (0)
- Thursday, 5/18, Trianon Ballroom, 5:00 pm–6:00 pm Theme II: Should Dihydropyridines Be Used for First Line Treatment?SHOULD DIHYDROPYRIDINES BE USED FOR FIRST LINE TREATMENT? (1995) (0)
- Letter to the EditorThe Authors Reply (2012) (0)
- Introduction to focused section on calcium antagonists and the kidney (1990) (0)
- Impact of hypertension and other coronary risk factors on cardiovascular disease: implications for coronary artery disease and congestive heart failure (1999) (0)
- NATRIURESIS OF WATER IMMERSION 229 hypertension , cardiovascular disease , or diabetes (2005) (0)
- Defining the Optimal Dialysis Regimen for Improving Left Ventricular Structure and Function: An Urgent Need. (2020) (0)
- Therapy of Renal Disorders in Liver Disease (1984) (0)
- In memoriam: Norman K. Hollenberg, MD, PhD, 1936–2020 (2020) (0)
- P-259: Effects of type II diabetes mellitus on the comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients (2001) (0)
- Calcium antagonists and hypertension : Evolving perspectives-1996 (1996) (0)
- OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. (2016) (0)
- Pathogenesis of Edema in Cirrhosis (1984) (0)
- Studies of the Renin-aldosterone System and Sodium Homeostasis During Simulated Weightlessness: Application of the Water Immersion Model to Man (1972) (0)
- A symposium : calcium antagonists in hypertension : evolving perspectives (1997) (0)
- Calcium antagonists and renal hemodynamics: implications for renal protection. (1991) (0)
- Diltiazem and Renal Hemodynamics: Implications for Renal Protection (1991) (0)
- Prescribing patterns of renin-angiotensin-aldosterone-system inhibitors are inconsistent with guidelines for treatment of cardio renal comorbidities (2015) (0)
- Studies of acid-base homeostasis during simulated weightlessness: Application of the water immersion model to man (1975) (0)
- Calcium antagonists and the progression of chronic (1998) (0)
- Josep Trueta and Renal Sympathetic Activation. (2020) (0)
- Cardiovascular Complications in Patients with Renal Disease (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Murray Epstein?
Murray Epstein is affiliated with the following schools:
